DelMar Pharmaceuticals, Inc. (DMPWW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

DelMar Pharmaceuticals, Inc. (DMPWW) Healthcare & Pipeline Overview

Kintara Therapeutics, formerly DelMar Pharmaceuticals, is a clinical-stage biotechnology firm developing VAL-083 for drug-resistant solid tumors and REM-001 for cutaneous metastatic breast cancer. With a strategic collaboration in China, Kintara aims to commercialize novel anti-cancer therapies in underserved markets, operating with a lean team.

What Is the Investment Thesis for DMPWW?

Kintara Therapeutics presents a high-risk, high-reward investment opportunity. The company's value is primarily tied to the successful development and commercialization of VAL-083 and REM-001. Positive Phase III trial results for VAL-083 in glioblastoma multiforme (GBM) could be a significant catalyst, potentially leading to accelerated regulatory approval and market adoption. The strategic collaboration with Guangxi Wuzhou Pharmaceutical for VAL-083 in China offers access to a large and growing market. However, the company's small size and limited resources pose significant challenges. Failure to secure additional funding or achieve clinical trial milestones could negatively impact the stock. The current P/E ratio of -3.60 reflects the company's lack of profitability, highlighting the speculative nature of the investment. Investors should carefully consider the clinical and regulatory risks associated with drug development, as well as the company's financial position.

Based on FMP financials and quantitative analysis

DMPWW Key Highlights

Kintara Therapeutics is focused on developing therapies for drug-resistant solid tumors, addressing a critical unmet need in oncology.

• VAL-083, a Phase III-ready therapeutic, targets glioblastoma multiforme (GBM) and other solid tumors, offering potential for significant market impact.
• REM-001, a late-stage photodynamic therapy, is being developed for cutaneous metastatic breast cancer and other indications.
• Strategic collaboration with Guangxi Wuzhou Pharmaceutical provides access to the Chinese market for VAL-083.
• The company operates with a lean structure of 2 employees, reflecting a focus on efficient drug development.

Who Are DMPWW's Competitors?

DMPWW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DMPWW's Key Strengths?

Late-stage clinical assets (VAL-083 and REM-001).

• Targeting unmet medical needs in oncology.
• Strategic collaboration with Guangxi Wuzhou Pharmaceutical.
• Lean operating structure.

What Are DMPWW's Weaknesses?

Limited financial resources.

• Small team with only 2 employees.
• Dependence on successful clinical trial outcomes.
• Lack of profitability.

What Could Drive DMPWW Stock Higher?

Phase III trial results for VAL-083 in glioblastoma multiforme (GBM).

• Regulatory approval decisions for VAL-083 and REM-001.
• Potential for additional partnerships and collaborations.
• Expansion of VAL-083 into new indications.
• Commercialization of REM-001.

What Are the Key Risks for DMPWW?

Financial-distress signal — its Altman Z-Score of -32.83 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for VAL-083 and REM-001.
• Regulatory hurdles and delays.
• Competition from other oncology companies.
• Inability to secure additional funding.
• Limited financial resources and small team.

What Are the Growth Opportunities for DMPWW?

• Expansion of VAL-083 into new indications: Kintara has the opportunity to expand the use of VAL-083 beyond glioblastoma multiforme (GBM) to other solid tumors, such as ovarian cancer and non-small cell lung cancer. These indications represent significant market opportunities, with a combined market size estimated at over $50 billion. Successful clinical trials in these new indications could significantly increase the value of VAL-083 and expand Kintara's market reach. The timeline for this expansion depends on the availability of funding and the progress of clinical trials, with potential for initial results within the next 2-3 years.
• Commercialization of REM-001: The successful commercialization of REM-001 for cutaneous metastatic breast cancer and other indications represents another key growth opportunity for Kintara. The market for photodynamic therapy is growing, driven by increasing demand for non-invasive cancer treatments. REM-001 has the potential to capture a significant share of this market, particularly if it demonstrates superior efficacy and safety compared to existing therapies. The timeline for commercialization depends on regulatory approval and the establishment of a sales and marketing infrastructure, with potential for launch within the next 3-5 years.
• Partnerships and collaborations: Kintara can pursue additional partnerships and collaborations to accelerate the development and commercialization of its pipeline. Collaborations with larger pharmaceutical companies can provide access to funding, expertise, and distribution networks. The existing partnership with Guangxi Wuzhou Pharmaceutical demonstrates the potential of this strategy. Expanding its network of partners could significantly enhance Kintara's ability to bring its therapies to market and maximize their commercial potential. These partnerships could materialize within the next 1-2 years.
• Geographic expansion: Kintara can expand its geographic reach beyond China by seeking regulatory approval and commercializing its therapies in other markets, such as the United States and Europe. These markets represent significant revenue opportunities, but also require substantial investment in clinical trials, regulatory affairs, and sales and marketing. The timeline for geographic expansion depends on the availability of funding and the progress of regulatory approvals, with potential for initial expansion within the next 3-5 years.
• Acquisition or merger: Kintara could be acquired by a larger pharmaceutical company seeking to expand its oncology pipeline. The company's late-stage assets, VAL-083 and REM-001, could be attractive to companies looking to bolster their presence in the cancer therapeutics market. An acquisition or merger could provide Kintara's shareholders with a significant return on investment. The timing of a potential acquisition is uncertain, but it could occur within the next 1-3 years.

What Are DMPWW's Competitive Advantages?

• Patented drug candidates with potential for market exclusivity.
• Late-stage clinical assets with de-risked development pathways.
• Strategic collaboration for access to the Chinese market.
• Focus on underserved patient populations with limited treatment options.

What Does DMPWW Do?

Kintara Therapeutics, Inc., originally incorporated as DelMar Pharmaceuticals in 2009, is a clinical-stage drug development company dedicated to discovering, developing, and commercializing innovative anti-cancer therapies. The company's primary focus is on addressing unmet medical needs in cancer treatment, particularly for patients with drug-resistant and difficult-to-treat tumors. Kintara's pipeline features two late-stage, Phase III-ready therapeutics: VAL-083 and REM-001. VAL-083 is a DNA-targeting agent being developed for the treatment of drug-resistant solid tumors, including glioblastoma multiforme (GBM), ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma (DIPG). GBM is a particularly aggressive form of brain cancer with limited treatment options, making VAL-083 a potentially valuable therapy for this patient population. REM-001 is a late-stage photodynamic therapy designed for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China, expanding its reach into the Chinese market. Headquartered in San Diego, California, Kintara Therapeutics operates with a small team of two employees, reflecting a lean and focused approach to drug development. The company changed its name from DelMar Pharmaceuticals to Kintara Therapeutics in August 2020, marking a new chapter in its corporate evolution.

What Products and Services Does DMPWW Offer?

• Develops anti-cancer therapies.
• Focuses on drug-resistant solid tumors.
• Conducts clinical trials for VAL-083 and REM-001.
• Targets glioblastoma multiforme (GBM) with VAL-083.
• Develops photodynamic therapy for cutaneous metastatic breast cancer.
• Collaborates with Guangxi Wuzhou Pharmaceutical for commercialization in China.

How Does DMPWW Make Money?

• Develops and patents novel anti-cancer therapies.
• Out-licenses or partners for commercialization of therapies.
• Generates revenue through milestone payments and royalties.
• Focuses on indications with unmet medical needs.

What Industry Does DMPWW Operate In?

Kintara Therapeutics operates within the biotechnology industry, a sector characterized by high risk and high reward. The industry is driven by innovation and the development of novel therapies for unmet medical needs. The competitive landscape is intense, with numerous companies vying to develop and commercialize new drugs. Kintara's focus on drug-resistant solid tumors positions it within a niche market with significant potential. The global oncology market is projected to reach $400 billion by 2030, driven by an aging population and increasing cancer incidence. Kintara's success depends on its ability to navigate the complex regulatory landscape, secure funding, and achieve clinical trial milestones.

Who Are DMPWW's Key Customers?

• Cancer patients with drug-resistant solid tumors.
• Hospitals and oncology clinics.
• Pharmaceutical companies through partnerships and licensing agreements.

How DelMar Pharmaceuticals, Inc. Is Valued

Relative to its peer group, DMPWW's quantitative score of 44/100 is below the peer average of 71/100.

Company Profile

DelMar Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. The company is led by CEO Robert E. Hoffman CPA.

Key Financial Metrics

Its free cash flow yield is -20.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -24.1%, the inverse of the P/E and a quick read on earnings relative to price.

DelMar Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -32.83 places it in the distress zone, a signal of elevated financial risk.

DMPWW Financials

DMPWW Latest News

No recent news available for DMPWW.

DMPWW Analyst Consensus

DMPWW MoonshotScore

What Investors Ask About DelMar Pharmaceuticals, Inc. (DMPWW) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources